Man Group PLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Man Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $57.6 Million - $60.6 Million	-397,627 Reduced 91.25%	38,145 $5.77 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $36.2 Million - $63.6 Million	435,772 New	435,772 $63.5 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $530,330 - $745,252	-5,365 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $352,909 - $563,432	5,365 New	5,365 $521,000
Q3 2020 Nov 16, 2020	SELL	$59.04 - $77.95 $1.71 Million - $2.25 Million	-28,884 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $837,924 - $2.14 Million	28,884 New	28,884 $2.11 Million
Q3 2019 Nov 14, 2019	SELL	$37.38 - $49.47 $8.14 Million - $10.8 Million	-217,868 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $6.74 Million - $11.4 Million	169,384 Added 349.36%	217,868 $9.54 Million
Q1 2019 May 15, 2019	BUY	$34.52 - $53.29 $1.67 Million - $2.58 Million	48,484 New	48,484 $2.5 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.